Market Research Report
Asia Pacific Exosome Diagnostic and Therapeutic Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||837247|
|Published||Content info||75 Pages
Delivery time: 2-3 business days
|Asia Pacific Exosome Diagnostic and Therapeutic Market Forecast 2019-2027|
|Published: May 13, 2019||Content info: 75 Pages||
The global exosome diagnostic and therapeutic market by the Asia Pacific region is estimated to grow from $XX million in 2018 to $XX million by 2027, at a CAGR of 28.19% between 2019 and 2027.
The market for exosome diagnostic and therapeutic in APAC is mainly driven by the increase in the pervasiveness of cancer, rising government and non-government initiatives and the advancement in technology. In 2018, the diagnostic application segment accounted for the largest share of approx. XX% of the overall exosome diagnostic and therapeutic market.
Japan, China, India, Australia, South Korea, and other countries together forming the Rest of Asia Pacific regional segment are the major economies shaping up the market trends of the regional market. Asia-Pacific is a solidly packed region, with China being the most populated country. So, the country's growth, which is supplemented by the substantially larger base of cancer patients, will increase the demand for exosome diagnostic and therapeutic products.
Hitachi Chemical Diagnostics, Inc., Qiagen N.V., System Biosciences (SBI), Malvern Instruments Ltd., Codiak BioSciences, Capricor Therapeutics, Inc., Nanosomix Inc., Sistemic Ltd., MBL International Corporation, BioCat GmbH, Thermo Fisher Scientific Inc., EVOX Therapeutics Ltd., Exosome Diagnostics Inc., HansaBioMed Life Sciences Ltd. (acquired by Lonza), and Aethlon Medical, Inc. are some of the contending market players operating that are mentioned in the report.